![]() |
市場調查報告書
商品編碼
2088779
人工智慧在醫學影像領域的市場:按組件、影像技術、應用、最終用戶和部署模式分類-2026-2032年全球市場預測Artificial Intelligence in Medical Imaging Market by Component, Imaging Technology, Application, End-User, Deployment Type - Global Forecast 2026-2032 |
||||||
※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。
預計到 2032 年,醫學影像領域的人工智慧 (AI) 市場規模將達到 62.1 億美元,複合年成長率為 18.12%。
| 主要市場統計數據 | |
|---|---|
| 基準年 2025 | 19.3億美元 |
| 預計年份:2026年 | 22.8億美元 |
| 預測年份:2032年 | 62.1億美元 |
| 複合年成長率 (%) | 18.12% |
人工智慧在醫學影像領域的應用正從實驗性影像分析轉向規範化的臨床應用,涵蓋放射學、循環系統、腫瘤學、神經科、病理學相關影像學以及急診醫學等領域。最先進的應用包括人工智慧放射學軟體、基於深度學習的影像重建、分流演算法、病灶檢測、分割、工作流程最佳化以及與PACS、RIS、VNA和電子健康記錄整合的臨床決策支援。
市場格局正受到三大相互關聯的變革的重塑:臨床檢驗演算法、企業應用以及監管成熟度。買家不再將人工智慧工具視為獨立的檢測產品,而是優先考慮能夠提供更快處理速度、更少報告差異、更高放射科醫生效率以及與現有影像基礎設施整合的互通平台。
人工智慧的累積效應在檢查量大、時間緊迫的影像檢查流程中最為顯著。以人工智慧為基礎的分流系統能夠辨識疑似顱內出血、肺動脈栓塞、氣胸、中風和嚴重胸部異常等觀察,從而優先處理緊急檢查。在篩檢項目中,人工智慧有助於簡化乳房X光攝影檢查、肺結節評估、糖尿病眼科疾病影像檢查和骨折辨識等流程,提升檢測與解讀效率。
北美在醫學影像人工智慧商業化方面處於領先地位,這得益於其龐大的影像檢查量、先進的醫院IT基礎設施、大規模的臨床研究網路,以及FDA對人工智慧/機器學習醫療設備清晰的核准流程。儘管美國仍然是受監管的人工智慧放射學軟體的主要首發市場,但加拿大正透過其省級數位醫療系統、隱私框架和專注於安全臨床部署的大學醫院網路,推動負責任的人工智慧應用。
隨著都市區醫院增加對數位影像技術的投資,而農村醫療系統也亟需可擴展的診斷支持,東協正成為人工智慧在醫學影像領域極具發展潛力的地區。在印尼、越南、泰國、馬來西亞、新加坡和菲律賓,由於各地在獲取專科醫生資源方面存在差異,以及透過區域數位健康策略改善網路連接和臨床數據交換,雲端人工智慧、遠端放射學和攜帶式超音波分析技術顯得尤為重要。
美國擁有全球最大的受監管人工智慧成像市場,這得益於FDA的批准、大學醫院、企業放射科網路以及與PACS和EHR系統整合的臨床工作流程的廣泛應用。加拿大透過其公共醫療保健系統和以隱私為中心的管治,優先考慮負責任的人工智慧應用。與此同時,墨西哥和巴西正在利用數位醫療的擴展來改善公共和私人醫療系統診斷服務的可近性。在歐洲,英國正透過NHS計畫投資人工智慧診斷,而德國、法國、義大利和西班牙則在創新與嚴格的資料保護、醫療設備法規以及放射科醫生短缺等挑戰之間尋求平衡。儘管國際技術流動受到限制,俄羅斯仍保持其國內人工智慧和成像能力,專注於本地部署平台。
產業領導者應優先考慮人工智慧能夠提升速度、準確性、一致性或可及性的具有臨床意義的應用情境。最大的機會在於急診分流、癌症篩檢、影像重建、定量影像、自動化報告、簡化臨床工作流程以及提高放射科醫生的工作效率。
本執行摘要基於檢驗的公共領域證據、監管資料庫、衛生監管機構指南以及可觀察到的行業應用趨勢。主要資訊來源包括美國食品藥物管理局 (FDA) 的人工智慧/機器學習醫療設備清單、世界衛生組織 (WHO) 的人力資源和疾病負擔數據、歐盟人工智慧法律要求、各國數位健康戰略、醫療設備監管指南以及經同行評審的人工智慧輔助成像領域表現證據。
醫學影像領域的人工智慧是醫療人工智慧領域中最成熟的領域之一,因為它能夠滿足諸如診斷速度、影像工作、放射科效率和臨床一致性等可衡量的需求。當演算法經過檢驗、規範、整合到工作流程中並在部署後進行監控時,其價值才能得到最大程度的體現。
The Artificial Intelligence in Medical Imaging Market is projected to grow by USD 6.21 billion at a CAGR of 18.12% by 2032.
| KEY MARKET STATISTICS | |
|---|---|
| Base Year [2025] | USD 1.93 billion |
| Estimated Year [2026] | USD 2.28 billion |
| Forecast Year [2032] | USD 6.21 billion |
| CAGR (%) | 18.12% |
Artificial intelligence in medical imaging is moving from experimental image analysis to regulated clinical deployment across radiology, cardiology, oncology, neurology, pathology-adjacent imaging, and emergency care. The strongest adoption is concentrated in AI radiology software, deep learning image reconstruction, triage algorithms, lesion detection, segmentation, workflow orchestration, and clinical decision support connected to PACS, RIS, VNA, and electronic health records.
The commercial case is supported by measurable healthcare pressure. The World Health Organization projects a global shortfall of 10 million health workers by 2030, while aging populations and chronic disease are increasing demand for CT, MRI, ultrasound, X-ray, mammography, and nuclear medicine. FDA public data also show more than 950 AI/ML-enabled medical devices authorized by 2024, with radiology representing the largest clinical category, confirming medical imaging as the leading regulated entry point for healthcare AI.
The market landscape is being reshaped by three linked shifts: clinically validated algorithms, enterprise deployment, and regulatory maturity. Buyers are no longer evaluating AI tools as isolated detection products; they are prioritizing interoperable platforms that improve turnaround time, reduce reporting variation, support radiologist productivity, and integrate with existing imaging informatics infrastructure.
Generative AI and multimodal models are also changing product roadmaps, but adoption remains anchored in evidence, safety, and workflow fit. The EU Artificial Intelligence Act, FDA software-as-a-medical-device oversight, the International Medical Device Regulators Forum framework, and growing hospital AI governance programs are pushing vendors toward transparent performance monitoring, cybersecurity controls, bias testing, clinical risk management, and post-market surveillance.
The cumulative impact of artificial intelligence is most visible in high-volume, time-sensitive imaging pathways. AI-based triage can flag suspected intracranial hemorrhage, pulmonary embolism, pneumothorax, stroke-related findings, and critical chest abnormalities so radiology teams can prioritize urgent studies. In screening programs, AI supports detection and reading efficiency in mammography, lung nodule assessment, diabetic eye imaging, and fracture identification.
Operationally, AI reduces repetitive measurement tasks, accelerates image reconstruction, standardizes quantitative reporting, and helps manage backlog. The impact is not a replacement of clinicians; it is a shift toward augmented radiology, where machine learning handles pattern recognition and workflow automation while physicians retain diagnostic accountability, final interpretation, and patient-level clinical responsibility.
North America leads AI medical imaging commercialization because of high imaging volumes, advanced hospital IT infrastructure, large clinical research networks, and a clear FDA pathway for AI/ML-enabled medical devices. The United States remains the primary launch market for regulated AI radiology software, while Canada is advancing responsible AI through provincial digital health systems, privacy frameworks, and academic hospital networks focused on safe clinical implementation.
Europe is shaped by strong research institutions, national radiology societies, and the EU AI Act, which classifies many AI medical devices as high risk and raises expectations for data quality, human oversight, transparency, and post-market monitoring. Asia-Pacific is scaling rapidly as China, Japan, South Korea, India, and Australia combine large patient populations, national AI strategies, aging demographics, and expanding imaging capacity. Latin America is seeing rising demand where AI can help extend access in Brazil and Mexico; the Middle East is accelerating adoption through digital hospital investments in the UAE and Saudi Arabia; and Africa shows practical need for AI-enabled teleradiology and point-of-care imaging support, with South Africa acting as a key implementation hub.
ASEAN is becoming a high-potential region for AI in medical imaging because urban hospitals are investing in digital imaging while rural systems need scalable diagnostic support. Cloud-enabled AI, teleradiology, and portable ultrasound analytics are especially relevant where specialist access is uneven across Indonesia, Vietnam, Thailand, Malaysia, Singapore, and the Philippines, and where regional digital health strategies are improving connectivity and clinical data exchange.
The GCC is accelerating AI adoption through national health modernization programs, including Saudi Vision 2030 and the UAE National Strategy for Artificial Intelligence 2031, with hospitals prioritizing smart imaging departments, radiology workflow automation, and secure health data platforms. The European Union is setting the compliance benchmark through the EU AI Act, GDPR, and MDR-aligned medical device expectations. BRICS markets offer scale, large imaging backlogs, and unmet diagnostic demand across China, India, Brazil, Russia, and South Africa, while the G7 remains central for premium imaging systems, reimbursement evidence, clinical validation, and regulatory convergence. NATO countries add emphasis on cybersecurity, resilience, secure health data exchange, and operational continuity for connected imaging infrastructure.
The United States is the largest regulated AI imaging market, supported by FDA authorizations, academic medical centers, enterprise radiology networks, and widespread deployment of PACS and EHR-connected clinical workflows. Canada emphasizes responsible AI deployment through public health systems and privacy-focused governance, while Mexico and Brazil are using digital health expansion to improve diagnostic access across public and private systems. In Europe, the United Kingdom is investing in AI diagnostics through NHS programs, and Germany, France, Italy, and Spain are balancing innovation with strict data protection, medical device regulation, and radiology workforce pressures. Russia maintains domestic AI and imaging capabilities despite constrained international technology flows and a stronger focus on locally deployable platforms.
China is scaling AI imaging through large hospital networks, national AI policy support, and NMPA oversight, while India's diagnostic demand is supported by expanding health coverage, digital health infrastructure, and the need to serve large underserved populations. Japan and South Korea are strong in aging-related imaging, robotics, semiconductor-enabled medical technology, and advanced electronics. Australia combines high-quality clinical research with telehealth maturity and rural imaging needs, making it a practical market for validated AI radiology, remote reporting, and workflow optimization tools.
Industry leaders should prioritize clinically meaningful use cases where AI improves speed, accuracy, consistency, or access. The strongest opportunities are in emergency triage, cancer screening, image reconstruction, quantitative imaging, reporting automation, clinical workflow orchestration, and radiologist productivity enhancement.
Vendors should build evidence packages that include external validation, subgroup performance, real-world monitoring, cybersecurity documentation, data provenance, and integration proof with PACS, RIS, EHR, VNA, and cloud environments. Providers should establish AI governance committees, define radiologist-in-the-loop workflows, monitor algorithm drift, validate performance on local populations, and negotiate contracts based on measurable operational and clinical outcomes rather than claims of general automation.
This executive summary is developed from verified public-domain evidence, regulatory databases, health authority guidance, and observable industry adoption signals. Core inputs include FDA AI/ML-enabled medical device listings, WHO workforce and disease-burden data, EU AI Act requirements, national digital health strategies, medical device regulatory guidance, and peer-reviewed evidence on AI-assisted imaging performance.
The methodology prioritizes triangulation across regulatory approvals, clinical workflow relevance, geographic adoption indicators, infrastructure readiness, and documented healthcare system pressures. Market interpretation excludes unsupported forecasts and focuses on observable drivers such as imaging demand, workforce constraints, reimbursement scrutiny, data governance, cybersecurity requirements, interoperability standards, and post-deployment performance monitoring.
Artificial intelligence in medical imaging has become one of the most mature areas of healthcare AI because it addresses measurable needs in diagnostic speed, imaging workload, radiology productivity, and clinical consistency. Its value is strongest when algorithms are validated, regulated, integrated into workflow, and monitored after deployment.
The next phase of adoption will favor organizations that combine clinical evidence with enterprise scalability, ethical data practices, cybersecurity readiness, and measurable productivity gains. As imaging volumes increase and specialist shortages persist, AI-enabled diagnostic imaging will remain a strategic priority for health systems, technology vendors, payers, and policymakers worldwide.